<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860221</url>
  </required_header>
  <id_info>
    <org_study_id>Knee blood</org_study_id>
    <nct_id>NCT02860221</nct_id>
  </id_info>
  <brief_title>Intravenous Versus Topical Administration of Low Dose Epinephrine Plus Combined Administration of Intravenous and Topical Tranexamic Acid (TXA)for Primary Total Knee Arthroplasty</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the blood loss of intravenous and topical
      administration of low dose epinephrine plus combined administration of intravenous and
      topical tranexamic acid for primary total knee arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date>July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total blood loss on the post-operative day 1</measure>
    <time_frame>1 day post-operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin (Hb)</measure>
    <time_frame>7 day</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit (Hct)</measure>
    <time_frame>7 day</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood platelet count (PLT)</measure>
    <time_frame>7 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operation Hospital for special surgery score (HSS)</measure>
    <time_frame>3 months</time_frame>
    <description>Scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative and post-operation range of motion (ROM) of operated knee joint (degree)</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>There is only one Unit of Measure for ROM, it is degree</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay (days)</measure>
    <time_frame>3 months</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with infection</measure>
    <time_frame>3 months</time_frame>
    <description>Post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deep vein thrombosis (DVT) cases</measure>
    <time_frame>1 month</time_frame>
    <description>Post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pulmonary embolism (PE) cases</measure>
    <time_frame>1 month</time_frame>
    <description>Post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>3 hours</time_frame>
    <description>Post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intravenous fluid administration on the operation day</measure>
    <time_frame>1 day</time_frame>
    <description>Milliliter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total blood loss on the post-operative day 3</measure>
    <time_frame>3 day post-operation</time_frame>
    <description>Milliliter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reaction time (R-time)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of thrombus formation (K time)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum amplitude (MA)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of thrombus formation (α-angle)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lysis rate at 30 min (LY30)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation index (CI)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin(IL)-1β</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin(IL)-6</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin(IL)-8</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor (TNF)-α</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin(IL)-10</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound score</measure>
    <time_frame>14 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion rate</measure>
    <time_frame>7 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion volume (mL)</measure>
    <time_frame>7 day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Intravenous epinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) low dose epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical epinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No epinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid (TXA)</intervention_name>
    <description>IV and topical administration</description>
    <arm_group_label>Intravenous epinephrine</arm_group_label>
    <arm_group_label>Topical epinephrine</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <arm_group_label>Intravenous epinephrine</arm_group_label>
    <arm_group_label>Topical epinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients between the ages of 20 and 75 who were diagnosed with osteoarthritis of
             the knee and scheduled for an elective primary total knee arthroplasty and those who
             were willing and able to return for follow-up over at least a 6-month postoperative
             period

        Exclusion Criteria:

          -  Acute coronary syndrome &lt; 6 months

          -  Glaucoma,pheochromocytoma, thyrotoxicosis, digoxin intoxication, serum potassium &lt; 3.0
             mmol, alcohol abuse, premenopausal women

          -  Current treatment with adenosine diphosphate (ADP) receptor antagonists, Factor Xa or
             thrombin inhibitors,heparin (excluding Low Molecular Weight Heparin (LMWH) for
             perioperative thromboprophylaxis), tricyclic antidepressants, or monoamine
             oxidase（MAO) or Catechol-O-methyltransferase (COMT) inhibitors

          -  Patients with history of thromboembolic disease, bleeding disorder

          -  Patients with history of renal impairment, cardiovascular diseases (previous
             myocardial infarction, atrial fibrillation) or cerebrovascular conditions (previous
             stroke or peripheral vascular surgery)

          -  Allergy to TXA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weinan Zeng, doctor</last_name>
      <phone>+8615023100103</phone>
      <email>weinanzeng@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>Liu Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Arthroplasty, Replacement, Knee</keyword>
  <keyword>Epinephrine</keyword>
  <keyword>Tranexamic acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

